{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:51:02Z","timestamp":1773319862545,"version":"3.50.1"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T00:00:00Z","timestamp":1407196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"abstract":"<jats:p>This study describes the development and regression of crizotinib-associated complex renal cysts (CACRCs) in a female patient with ALK-positive advanced non-small cell lung cancer with an ongoing complete response while on continuous crizotinib treatment. The clinical context of crizotinib use requires frequent imaging studies; therefore observation is probably the best approach to CACRC management in asymptomatic patients. The natural history of CACRCs remains unknown, and large-scale longitudinal follow-up studies of these cysts are eagerly awaited.<\/jats:p>","DOI":"10.1634\/theoncologist.2014-0216","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T05:47:48Z","timestamp":1407304068000},"page":"1008-1010","source":"Crossref","is-referenced-by-count":30,"title":["Spontaneous Regression of Crizotinib-Associated Complex Renal Cysts During Continuous Crizotinib Treatment"],"prefix":"10.1093","volume":"19","author":[{"given":"Samuel J.","family":"Klempner","sequence":"first","affiliation":[{"name":"Chao Family Comprehensive Cancer Center and Division of Hematology Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Golnaz","family":"Aubin","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of California Irvine School of Medicine, Orange, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atreya","family":"Dash","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai-Hong Ignatius","family":"Ou","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center and Division of Hematology Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,8,5]]},"reference":[{"key":"2021122309064603800_B1","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1634\/theoncologist.2012-0311","article-title":"Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: A success story to usher in the second decade of molecular targeted therapy in oncology","volume":"17","author":"Ou","year":"2012","journal-title":"The Oncologist"},{"key":"2021122309064603800_B2","volume-title":"XALKORI U.S. Physician Prescribing Information","year":"2014"},{"key":"2021122309064603800_B3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/annonc\/mdt572","article-title":"Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC","volume":"25","author":"Ou","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122309064603800_B4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0009-9260(83)80238-4","article-title":"The incidence of simple renal cyst by computed tomography","volume":"34","author":"Tada","year":"1983","journal-title":"Clin Radiol"},{"key":"2021122309064603800_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1148\/radiology.158.1.3510019","article-title":"The current radiological approach to renal cysts","volume":"158","author":"Bosniak","year":"1986","journal-title":"Radiology"},{"key":"2021122309064603800_B6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5489\/cuaj.10023","article-title":"Guidelines on the management of renal cyst disease","volume":"4","author":"Whelan","year":"2010","journal-title":"Can Urol Assoc J"},{"key":"2021122309064603800_B7","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122309064603800_B8","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122309064603800_B9","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2014-0216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0216","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/9\/1008\/41862075\/oncolo_19_9_1008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/9\/1008\/41862075\/oncolo_19_9_1008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T09:07:19Z","timestamp":1640250439000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/9\/1008\/6399568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,5]]},"references-count":9,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,8,5]]},"published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0216","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,9,1]]},"published":{"date-parts":[[2014,8,5]]}}}